Edwards Lifesciences Longtime Chair To Retire
By Ben Glickman
Edwards Lifesciences said Tuesday that chair Michael Mussallem planned to retire about a year after stepping down as chief executive.
The Irvine, Calif.-based company said in a regulatory filing that Mussallem, who served as CEO of Edwards from 2000 to 2023, is expected to be succeeded as chair by Nicholas Valeriani, an independent director.
Mussallem retired as CEO at the 2023 annual meeting, transitioning into the non-executive chair role. He was succeeded in the CEO role by Bernard Zovighian.
The company's annual meeting is scheduled for May 7.
Edwards said in the filing that board member Martha Marsh had reached the retirement age outlined in the company's governance guidelines.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 26, 2024 16:42 ET (20:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software